PUBLIC UTILITIES CODE SECTION 381 HOW TO

The diversity of populations, regions, and resource levels from which the data originate increases the generalizability of the evidence generated and supports comparisons across them. Access to data facilitates science, improves scientific transparency and integrity, and has played a substantial role in the generation of knowledge that has led to better patient management and vaccine production for COVID-19 11. The objective of the dataset is to accelerate understanding of COVID-19 through access to detailed clinical information on infected patients from a range of settings. The number of patients included in the dataset continues to grow as data collection continues across the globe. Figure 1 shows the number of patients per country included in the database as of September 2021 1, 4, 10. Clinical teams in 1,559 participating institutions collected the data.

Between January 2020 and September 2021, information about the clinical presentation, treatment, and outcomes of more than 705,000 patients with COVID-19, hospitalized across 62 countries, was aggregated to form the ISARIC-COVID-19 dataset. Therefore, the continuation of high-quality, globally-representative research is critical – as are the data required to deliver it.Īt the beginning of the COVID-19 outbreak, ISARIC adapted the ISARIC-WHO Clinical Characterization Protocol and data tools 7 to facilitate global research collaboration and accelerate the understanding of COVID-19 as part of the public health response to the pandemic 1, 8, 9. Despite unprecedented success in the rapid generation of vaccines and effective treatments, COVID-19 continues to cause severe and widespread health consequences 5, 6.

In June 2022, there were more than 500 million reported cases and more than 6 million deaths. The fatality rate of COVID-19 varies substantially across different locations, which may reflect differences in population age, comorbidities, vaccination status, and other factors 4. The initial focus was on the clinical characterisation of COVID-19, the disease caused by SARS-CoV-2, which mainly affects the respiratory system 2. In January 2020, ISARIC launched a research response to the emergence of a novel severe acute respiratory syndrome coronavirus (SARS-COV-2), detected weeks earlier in Wuhan, China 2, 3. The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) is a global federation of clinical research networks collaborating to prevent illness and death from infectious disease outbreaks through proficient and agile research response 1.

PUBLIC UTILITIES CODE SECTION 381 HOW TO

Here, we present the dataset characteristics, explain its architecture and how to gain access, and provide tools to facilitate its use. The data include signs and symptoms, pre-existing comorbidities, vital signs, chronic and acute treatments, complications, dates of hospitalization and discharge, mortality, viral strains, vaccination status, and other data. Patient data are available from acute hospital admissions with COVID-19 and outpatient follow-ups. The database includes data from more than 705,000 patients, collected in more than 60 countries and 1,500 centres worldwide. This dataset was compiled during the COVID-19 pandemic by a network of hospitals that collect data using the ISARIC-World Health Organization Clinical Characterization Protocol and data tools. The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) COVID-19 dataset is one of the largest international databases of prospectively collected clinical data on people hospitalized with COVID-19.

Public utilities code section 381